Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 21.67.
Forward PE Ratio (21.67) = Close Price ($142.85) / Consensus Forward EPS ($6.51)
FORWARD PE RATIO
21.67
SECTOR MEDIAN · HEALTHCARE
20.09
median of 67 covered companies
CURRENT VS SECTOR MEDIAN
+7.86%
vs the sector median at left
Insulet Corp.
Market Cap
$9.89B
Forward PE Ratio
21.67
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Insulet Corp. (PODD) | $9.89B | 21.67 |
| Henry Schein, Inc. (HSIC)vs › | $10.03B | 16.37 |
| Tempus AI, Inc. (TEM)vs › | $9.65B | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.54B | 36.56 |
| Molina Healthcare, Inc. (MOH)vs › | $10.38B | N/A |
| Universal Health Services, Inc. (UHS)vs › | $10.46B | 7.63 |
| Bio-Techne Corporation (TECH)vs › | $11.29B | 37.50 |
| DaVita Inc. (DVA)vs › | $11.79B | 12.42 |
| Align Technology, Inc. (ALGN)vs › | $12.61B | 15.40 |
| Oscar Health, Inc. (OSCR)vs › | $7.17B | 25.07 |
Trailing P/E
26.4
reported TTM EPS
Forward P/E
21.7
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $6.51 implies +21.7% EPS growth vs the reported trailing $5.35.
At today's $142.85 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $6.51 | $6.44 – $6.61 | 13 | 21.9x |
| 2027-12-31 | $7.77 | $7.18 – $8.13 | 15 | 18.4x |
| 2028-12-31 | $9.55 | $8.73 – $10.15 | 10 | 15.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
